{"filing":{"accession_number":"0001171843-26-004758","cik":"0001745114","ticker":"MOLN","company_name":"MOLECULAR PARTNERS AG","form":"6-K","filing_date":"2026-07-20","report_date":null,"primary_document":"f6k_072026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1745114/000117184326004758/f6k_072026.htm"},"events":[{"id":18691,"run_id":16808,"accession_number":"0001171843-26-004758","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces clinical progress in a Phase 2 trial of MP0317 for cholangiocarcinoma, including dosing of first patients, nine activated trial sites, and expected data in 2027. While this is a material operational milestone for a clinical-stage biotech company, it does not fit the specific `earnings_release` category (no financial results disclosed) nor any other named event type. The disclosure is clearly operational—a significant clinical development milestone—making `operational_other` the appropriate classification.","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-07-20","form":"6-K","submitted_at":null,"items":[{"id":17576,"accession_number":"0001171843-26-004758","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces clinical progress in a Phase 2 trial of MP0317 for cholangiocarcinoma, including dosing of first patients, nine activated trial sites, and expected data in 2027. While this is a material operational milestone for a clinical-stage biotech company, it does not fit the specific `earnings_release` category (no financial results disclosed) nor any other named event type. The disclosure is clearly operational—a significant clinical development milestone—making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:16:18.766696+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17576,"accession_number":"0001171843-26-004758","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces clinical progress in a Phase 2 trial of MP0317 for cholangiocarcinoma, including dosing of first patients, nine activated trial sites, and expected data in 2027. While this is a material operational milestone for a clinical-stage biotech company, it does not fit the specific `earnings_release` category (no financial results disclosed) nor any other named event type. The disclosure is clearly operational—a significant clinical development milestone—making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:16:18.766696+00:00","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-07-20"}]}